"Immunotherapy, Active" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Active immunization where vaccine is administered for therapeutic or preventive purposes. This can include administration of immunopotentiating agents such as BCG vaccine and Corynebacterium parvum as well as biological response modifiers such as interferons, interleukins, and colony-stimulating factors in order to directly stimulate the immune system.
| Descriptor ID |
D016233
|
| MeSH Number(s) |
E02.095.465.425.400.530 E05.478.550.600
|
| Concept/Terms |
Immunotherapy, Active- Immunotherapy, Active
- Active Immunotherapy
- Active Immunotherapies
- Immunotherapies, Active
Vaccine Therapy- Vaccine Therapy
- Therapy, Vaccine
- Therapies, Vaccine
- Vaccine Therapies
Immune RNA Manipulation- Immune RNA Manipulation
- Immune RNA Manipulations
- Manipulation, Immune RNA
- Manipulations, Immune RNA
- RNA Manipulation, Immune
- RNA Manipulations, Immune
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy, Active".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy, Active".
This graph shows the total number of publications written about "Immunotherapy, Active" by people in this website by year, and whether "Immunotherapy, Active" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 1 | 0 | 1 |
| 2002 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 2 | 1 | 3 |
| 2009 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy, Active" by people in Profiles.
-
Autologous Dendritic Vaccine Therapy in Metastatic Kidney Cancer: The ADAPT Trial and Beyond. Eur Urol Focus. 2022 05; 8(3):651-653.
-
New approaches to immunotherapy for metastatic castration-resistant prostate cancer. Clin Adv Hematol Oncol. 2019 May; 17(5):283-286.
-
Phase I study of an active immunotherapy for asymptomatic phase Lymphoplasmacytic lymphoma with DNA vaccines encoding antigen-chemokine fusion: study protocol. BMC Cancer. 2018 02 13; 18(1):187.
-
Advances in Therapeutic Cancer Vaccines. Adv Immunol. 2016; 130:191-249.
-
Intratumoral immunotherapy for melanoma. Cancer Immunol Immunother. 2015 Jul; 64(7):911-21.
-
MAS-1 adjuvant immunotherapy generates robust Th2 type and regulatory immune responses providing long-term protection from diabetes in late-stage pre-diabetic NOD mice. Autoimmunity. 2014 Aug; 47(5):341-50.
-
Identification of prostate-specific G-protein coupled receptor as a tumor antigen recognized by CD8(+) T cells for cancer immunotherapy. PLoS One. 2012; 7(9):e45756.
-
Modeling the economic value of a Chagas' disease therapeutic vaccine. Hum Vaccin Immunother. 2012 Sep; 8(9):1293-301.
-
Enhancement of cancer vaccine therapy by systemic delivery of a tumor-targeting Salmonella-based STAT3 shRNA suppresses the growth of established melanoma tumors. Cancer Res. 2011 Jun 15; 71(12):4183-91.
-
Chimeric Trop2 virus-like particles: a potential immunotherapeutic approach against pancreatic cancer. J Immunother. 2011 Apr; 34(3):251-63.